Peptides and protein drug delivery
While the peptide and protein therapeutic market has developed significantly in the past decades, delivery has limited their use. Although oral delivery is preferred, most are currently delivered intravenously or subcutaneously due to degradation and limited absorption in the gastrointestinal tract. Due to rapid progress in biotechnology, as well as gene technology, the industry can produce many potential therapeutic peptides and proteins in commercial quantities. Endogenous proteins and peptides play an important role in the regulation and integration of life processes and act with high specificity and potency. Peptides and proteins have great potential as therapeutics. Currently, the market for peptide and protein drugs is estimated to be greater than US$40 billion/year, or 10% of the pharmaceutical market. This market is growing much faster than that of small molecules and will make up an even larger proportion of the market in the future.
- Track 1-1 Recent advances in peptide and protein drug delivery
- Track 2-2 Peptidal drug delivery
- Track 3-3 Oral protein and peptide drug delivery
- Track 4-4 Polymers for protein and peptide drug delivery
- Track 5-5 Cell therapy